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Abstract
Introduction: Systemic inflammation (for example, following surgery) involves Toll-like receptor (TLR) signaling and
leads to an endocrine stress response. This study aims to investigate a possible influence of TLR2 and TLR4 single
nucleotide polymorphisms (SNPs) on perioperative adrenocorticotropic hormone (ACTH) and cortisol regulation in
serum of cardiac surgical patients. To investigate the link to systemic inflammation in this context, we additionally
measured 10 different cytokines in the serum.
Methods: A total of 338 patients admitted for elective cardiac surgery were included in this prospective
observational clinical cohort study. Genomic DNA of patients was screened for TLR2 and TLR4 SNPs. Serum
concentrations of ACTH, cortisol, interferon (IFN)-g, interleukin (IL)-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, tumor necrosis
factor (TNF)-a and granulocyte macrophage-colony stimulating factor (GM-CSF) were determined before surgery,
immediately post surgery and on the first postoperative day.
Results: Thirteen patients were identified as TLR2 SNP carriers, 51 as TLR4 SNP carriers and 274 patients as non-
carriers. Basal levels of ACTH, cortisol and cytokines did not differ among groups. In all three groups a significant,
transient perioperative rise of cortisol could be observed. However, only in the non-carrier group this was
accompanied by a significant ACTH rise. TLR4 SNP carriers had significant lower ACTH levels compared to non-
carriers (mean (95% confidence intervals)) non-carriers: 201.9 (187.7 to 216.1) pg/ml; TLR4 SNP carriers: 149.9 (118.4
to 181.5) pg/ml; TLR2 SNP carriers: 176.4 ((110.5 to 242.3) pg/ml). Compared to non-carriers, TLR4 SNP carriers
showed significant lower serum IL-8, IL-10 and GM-CSF peaks (mean (95% confidence intervals)): IL-8: non-carriers:
42.6 (36.7 to 48.5) pg/ml, TLR4 SNP carriers: 23.7 (10.7 to 36.8) pg/ml; IL-10: non-carriers: 83.8 (70.3 to 97.4) pg/ml,
TLR4 SNP carriers: 54.2 (24.1 to 84.2) pg/ml; GM-CSF: non-carriers: 33.0 (27.8 to 38.3) pg/ml, TLR4 SNP carriers: 20.2
(8.6 to 31.8) pg/ml). No significant changes over time or between the groups were found for the other cytokines.
Conclusions: Regulation of the immunoendocrine stress response during systemic inflammation is influenced by
the presence of a TLR4 SNP. Cardiac surgical patients carrying this genotype showed decreased serum
concentrations of ACTH, IL-8, IL-10 and GM-CSF. This finding might have impact on interpreting previous and
designing future trials on diagnosing and modulating immunoendocrine dysregulation (for example, adrenal
insufficiency) during systemic inflammation and sepsis.
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Toll-like receptors (TLRs) are known to play a crucial
r o l ei nt h ei n n a t ei m m u n er e s p o n s ei nm a m m a l s .T L R s
are involved in the recognition of pathogenic molecules
like lipopolysaccharide (LPS), lipoteichoic acid (LTA),
bacterial DNA and others [1]. Furthermore, there is
good evidence for the involvement of TLRs in the cross-
talk of immune system and the hypothalamic-pituitary-
adrenal (HPA) axis [2-5]. In TLR2 deficient mice, adre-
nal glands are significantly larger compared to wild-type
mice. However, the corticosterone plasma levels are sig-
nificantly lower in the deficient mice. Inducing a sys-
temic inflammation with bacte r i a lw a l lc o m p o n e n t si n
TLR2 deficient mice leads to an impaired release of
both corticosterone and pro-inflammatory cytokines
compared to wild-type animals [6]. A similar difference
of physiology and pathophysiology of the HPA axis
exists between wild-type and TLR4 deficient mice.
Under physiological conditions the cortex of the adrenal
glands is significantly enlarged and plasma concentra-
tions of corticosterone and the pro-inflammatory cyto-
kines tumor necrosis factor (TNF)-a, interleukin (IL)-1b
and IL-12 are significantly higher when compared to
wild-type animals. Systemic inflammation induces an
increase of corticosterone plasma concentration in wild-
type, but a decrease in TLR4 deficient mice [7].
In humans, single nucleotide polymorphisms (SNPs) are
described. For TLR2 the most investigated SNP is
Arg753Gln which is located in the coding region with a
prevalence of approximately 3 to 9.4% in the Cauca-
sian population [8-13]. Children carrying the SNP of
Arg753Gln are more susceptible to febrile infections com-
pared to non-carriers [13]. Furthermore, the Arg753Gln
polymorphism has been reported to increase the risk of
gram-positive and candida sepsis in critical ill patients
[8,10], and to increase restenosis rate in patients who
underwent percutaneous transluminal coronary angio-
plasty [14].
The two most investigated SNPs of TLR4 are
Asp299Gly and Thr399Ile. Six to 14% of the European
population are double heterozygote carriers, whereas less
than 0.3% carry either the Asp299Gly or the Thr399Ile
SNP alone [15]. Compared to non-carriers, Asp299Gly/
Thr399Ile carriers demonstrated a blunted decrease of
forced expiratory volume in one second in response to
LPS inhalation [16,17], and significant lower plasma levels
of the inflammatory markers IL-6, IL-1b and C-reactive
protein (CRP) in response to LPS injection [18].
Cardiac surgery leads to the activation of both the
immune system and the HPA axis. In particular the
application of extracorporal circulation, that is, cardio-
pulmonary bypass (CPB) with distinct contact between
blood and artificial surfaces induces complement system,
leucocyte activation and the release of cytokines, nitric
oxide and oxygen-free radicals [19,20]. The latter patho-
physiological changes lead to a systemic inflammatory
response and are associated with the release of adreno-
corticotropic hormone (ACTH), cortisol [21-23] and
various cytokines [24].
In this prospective observational clinical cohort study
we aimed to asses the impact of TLR2 and TLR4 poly-
morphisms on HPA axis regulation and cytokine release
related to systemic inflammation during/following car-
diac surgery. Primary endpoint was the influence of
TLR2 and TLR4 SNP on ACTH and cortisol regulation.
Secondary endpoint was the influence of TLR2 and
TLR4 SNP on systemic cytokine release.
Materials and methods
Patients
This prospective single center observational clinical
cohort study was approved by the local ethical review
committee (University Hospital Duesseldorf) and carried
out in compliance with the principles established in the
Helsinki Declaration. Written consent was obtained
from 383 patients undergoing elective cardiac surgery
(coronary artery bypass graft (CABG) and/or valve sur-
gery (VS) including replacement and reconstruction).
Inclusion criteria: age 18 or older, elective cardiac sur-
gery, on CPB. Exclusion criteria: cardiac surgery per-
formed without CPB, history of diseases affecting the
HPA axis, systemic or local treatment with glucocorti-
coids within 30 days before surgery.
Clinical management
Following standard oral benzodiazepine premedication
the night before surgery and one to two hours preopera-
tive on the day of operation, standard monitoring, per-
ipheral venous and arterial access were established prior
to induction. Anesthesia was induced with fentanyl (3 to
4 μg/kg) and thiopenthal (1 to 2 mg/kg). Following mus-
cle relaxation with pancuronium bromide (100 μg/kg),
the patient was intubated, ventilated and general
anesthesia was maintained using fentanyl and sevoflur-
ane (0.8 to 1.5 vol% end-tidal). Central venous access
was established, a rectal temperature probe and a urine
catheter were inserted. Prior to CPB the patient was
fully heparinized with 300 IU/kg heparin i.v. achieving
an activated clotting time (ACT) of longer than 400 sec-
onds. Every patient underwent standard nonpulsatile,
hypothermic (28°C to 32°C) CPB (roller pump: Stöckert,
Munich, Germany; membrane oxygenator: Cobe,
Arvada, CO, USA). Flow rate initially started at 2.4 L/
minute/m
2 and was further adjusted to maintain a mean
arterial blood pressure (MAP) of 60 mmHg. Heparin
was administered intermittently to maintain ACT
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was used for cardioplegia. At the end of surgery heparin
was antagonized with protamine (3 mg/kg) and after re-
warming patients’ temperature to a minimum of 34°C,
CPB was weaned off slowly with fluids and/or inotropic
agents infused according to central venous pressure or
MAP respectively. Patients, intubated, ventilated and
sedated were then transferred to the ICU.
Sampling
Beside routine pre- and postoperative blood tests three
consecutive blood samples were obtained from each
patient (supine position). Sample A (whole blood and
serum): Preoperative, between 07:00 and 09:00; Sample
B (serum): Postoperative, on arrival to the intensive care
unit (ICU); Sample C (serum): Postoperative Day 1,
between 07:00 and 09:00. Whole blood samples were
stored at -80°C, serum samples were centrifuged and
stored at -20°C until laboratory analysis.
DNA preparation and genotyping
DNA was extracted from whole blood by commercial
kits (QIAmp, Qiagen, Hilden, Germany). Genotyping for
TLR2 SNP Arg753Gln (rs5743708) and TLR4 SNPs
Asp299Gly (rs4986790) and Thr399Ile (rs4986791) was
done by melting curve analysis employing FRET probes
and the LightcyclerTM (Roche Diagnostics, Mannheim,
Germany) as described previously [25]. In brief, 10 to 50
ng genomic DNA was amplified using the following pri-
mers: forward: AGTGAGC-GGGATGCCTACT and
reverse: GACTTTATCGCAGCTCTCAGATTTAC for
TLR2; forward: ATTTAAAGAAATTAGGCTTCA-
TAAGCT and reverse: CCAAGAAGTTTG-AACT-
CATGGTAA for TLR4. Hybridisation FRET probes
CAAGCTGCAGAAGATAA-TGAACACCAAG-FL and
LC Red640-CCTACCTGGAGTGGCCCATGGACG for
R753Q gave rise to melting peaks at 60.9°C for the wild-
type allele and 65.4°C for the mutated allele. Hybridisa-
tion FRET probes CTACTACCTCGATGATATTATT-
GACTTATT-FL and LC Red640-AATTGTTTGACAAA
TGTTTCTTCATTTTCC for Asp299Gly and LC
Red705-ATTTTGGGACAACCAGCCTAAAGTAT and
CTTGAGTTTCAAAGGTTG-CTGTTCTCAAAGT-FL
for Thr399Ile gave rise to melting peaks at 62°C and
57.4°C or 67°C and 60.6°C for wild-type and mutated
alleles, respectively.
Measurements of ACTH and cortisol
ACTH and cortisol serum concentrations were mea-
sured by radioimmunoassays (Diagnostic System
Laboratories Deutschland DSL, Sinsheim, Germany) as
recently described [26]. Concentrations are given as
pg/ml for ACTH and μg/dl for cortisol.
Measurements of cytokines
Serum levels of interferon (IFN)-g,I L - 1 b, IL-2, IL-4, IL-
5, IL-6, IL-8, IL-10, TNF-a and granulocyte macro-
phage-colony stimulating factor (GM-CSF) (Human
Cytokine 10-Plex for Luminex™ laser, BioSource Eur-
ope, S.A. Nivelles, Belgium) were determined using the
microsphere array technique (Luminex 100 system,
Luminex Corp. Austin, TX, USA). Assays were per-
formed according to the manufacturer’s protocols [27].
This 10-Plex was chosen because it covers the most
important/investigated cytokines in human serum in the
context of acute systemic inflammation. Concentrations
are given as pg/ml. Detection limits (in pg/ml): IFN-g:5 ,
IL-1b: 15, IL-2: 6, IL-4: 5, IL-5: 3, IL-6: 3, IL-8: 3, IL-10:
5, TNF-a: 10, GM-CSF: 15.
Statistical analysis
Continuous values are displayed as means and 95% con-
fidence intervals or medians with interquartile range.
Continuous baseline data were tested for differences
between the groups TLR2 SNP, TLR4 SNP and non-car-
riers with two-sided Kruskal-Wallis-tests. Categorical
values are displayed as frequencies and percentages.
Categorical baseline data were tested for differences
between groups by two-sided Fisher’se x a c tt e s t s .T h e
time courses of cortisol, ACTH and cytokines were ana-
lysed by means of absolute changes from baseline for
time points A, B, and C in a linear mixed model. The
multiple visits per patient were taken into account.
Independence was used as working correlation matrix.
Pair wise contrasts were calculated to compare pairs of
groups with regard to differences in change from base-
line. The factors gender, height, weight, type of surgery,
duration of surgery, and outcome of 28-day follow-up
were included into the model. Backward selection was
used to identify significant factors at a level of 0.05.
Also visit and the interaction group visit were included
to test for differences in the course of the values over
time. Two-sided P-values below 0.05 were regarded as
statistically significant. Calculations were performed
using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Patient selection, demographic data and baseline
characteristics
All patients fulfilling inclusion criteria who granted
informed consent were consecutively enrolled over a
period of eight months. There were no changes in anes-
thetic, surgical, or perfusion techniques during this per-
iod. A total of 383 patients were included. Patients were
excluded who required reoperation within the period of
observation (n = 12), were unexpectedly operated with-
out CPB (n = 7) or received glucocorticoid therapy
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patients genotyping failed for technical reasons. Two
more patients identified as SNP carrier for both, TRL2
and TLR4 were excluded. For the remaining 346
patients, frequency distribution analyzes of cortisol- and
ACTH- concentrations in the baseline samples (A) fol-
lowed. To reduce the undue influence of subjects
demonstrating undetected HPA axis pathologies, preo-
perative systemic inflammation or measurement related
discrepancies, outliers were defined as values above
99.5% tolerance intervals (TI) and subjects demonstrat-
ing these outliers were excluded from analyzes. A total
of 338 patients, all European Caucasians were included;
13 patients were identified as TLR2,5 1a sTLR4 SNP
carriers, 274 patients were identified as non-carriers. All
TLR2 SNP carriers were heterozygous for Arg753Gln,
none homozygous. All TLR4 SNP carriers were hetero-
zygous for both, Asp299Gly and Thr399Ile. None was
heterozygous for Asp299Gly or Thr399Ile only. None
was homozygous for Asp299Gly or Thr399Ile, none of
the patients was identified to be homozygous for both
alleles. Each SNP was in Hardy-Weinberg equilibrium
(TLR2: P =0 . 7 2 ;TLR4: P = 0.13). Demographic data,
baseline characteristics and 28-day outcome did not dif-
fer between non-carriers, TLR2 SNP and TLR4 SNP car-
riers with the exception of beta-blocker intake (Table 1).
The difference in frequency of beta-blocker intake was
further analyzed and found to be absent when compar-
ing non-carriers with TLR4 SNP carriers (P = 0.1257).
ACTH and cortisol
Basal ACTH and cortisol serum levels did not differ
between the three genotypes (Figure 1a, b). In all three
genotypes cortisol levels significantly raised postopera-
tively at sample times B and C. However, only in the
non-carrier group this was accompanied by a significant
ACTH rise. At sample time C there was a significant
decrease of the ACTH levels compared to sample points
A and B in the non-carrier group. Neither in the TLR4
SNP nor in the TLR2 SNP carrier group there was a sig-
nificant difference in changes of ACTH serum concen-
t r a t i o n s .A ts a m p l et i m eBt h ea b s o l u t ec h a n g e so f
ACTH levels were significantly different between non-
carriers and TLR4 SNP carriers.
Cytokines
Basal cytokine levels did not differ between the three
genotypes (Figure 2a-c, Table 2). Levels of IFN-g in the
majority of the measurements were below the detection
limit and therefore not analyzed. No significant changes
over time or between the groups were found for the
cytokines IL-1b,I L - 2 ,I L - 4 ,I L - 5a n dT N F - a (Table 2).
IL-6 levels significantly rose on sample time B for all
genotype groups and on sample time C for non-carriers
Table 1 Demographic data and baseline characteristics of study population.
Non-carrier TLR2 SNP TLR4 SNP P-value
Number, n 274 13 51
Gender (M/F) 200/74 8/5 38/13 0.6236
Age, yr (median (IQR)) 69 (62 to 75) 74 (66 to 77) 71 (61 to 77) 0.1944
Weight, kg (median (IQR)) 80 (70 to 90) 80 (70 to 93) 80 (70 to 90) 0.7685
Height, m (median (IQR)) 1.72 (1.65 to 1.76) 1.68 (1.65 to 1.72) 1.73 (1.66 to 1.78) 0.2200
Time of surgery, h 4.0 (3.4 to 4.7) 3.8 (3.3 to 4.1) 3.8 (3.3 to 4.4) 0.2101
Diabetes mellitus, n (%) 96 (35) 5 (38) 12 (24) 0.2375
Admission medication
Beta-blocker, n (%) 215 (78) 13 (100) 35 (69) 0.0362
ACE inhibitor, n (%) 137 (50) 10 (77) 30 (59) 0.1048
Calcium channel-blocker, n (%) 39 (14) 4 (31) 4 (8) 0.0862
Diuretics, n (%) 138 (50) 5 (38) 25 (49) 0.7455
Nitrates, n (%) 68 (25) 3 (23) 11 (22) 0.9285
Type of surgery
CABG, n (%) 183 (67) 9 (69) 36 (71)
VS, n (%) 33 (12) 3 (23) 4 (8) 0.7542
CABG + VS, n (%) 43 (16) 1 (8) 7 (14)
Other, n (%) 15 (6) 0 (0) 4 (8)
28-day outcome
Survivor, n (%) 247 (93) 9 (75) 41 (89) 0.0753
Nonsurvivor, n (%) 19 (7) 3 (25) 5(11)
CABG, coronary artery bypass graft; IQR, interquartile range; TLR2 SNP, toll-like receptor2 single-nucleotide polymorphism carrier; TLR4 SNP, toll-like receptor4
single-nucleotide polymorphism carrier; VS, valve surgery.
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in the non-carrier group from sample time B to C. No
significant differences were found between the genotype
groups (Table 2). IL-8 levels were significantly elevated
on sample times B and C, declining significantly from B
to C in the non-carrier group. In the TLR4 SNP carrier
group no significant rise, but even significant lower IL-8
concentrations compared to non-carriers, could be
observed. However, there was a transient, significant
peak of IL-8 levels in the TLR2 SNP group, represented
by a significant rise from A to B and a significant drop
from B to C (Figure 2a). IL-10 levels peaked at sample
time B, that is, significantly increased from A to B and
subsequently significantly dropped from B to C in the
non-carrier and TLR4 SNP group. IL-10 peak concentra-
tions were significantly lower in TLR4 SNP carriers
compared to non-carriers (Figure 2b). GM-CSF levels
rose significantly from A to B in all three groups and
from A to C in non-carrier and TLR4 SNP carrier
patients. In the non-carrier group GM-CSF levels
dropped significantly from B to C. GM-CSF levels at
sample time B were significantly lower in the TLR4 SNP
group compared to non-carriers (Figure 2c).
Discussion
Systemic inflammation, as a result of major surgery or
sepsis, has a distinct effect on the immune-adrenal
crosstalk. We report for the first time of an association
between the presence of a SNP (here: TLR4)a n dp e r i o -
perative ACTH levels. Changes of ACTH levels were
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Day 1. TLR2 SNP, toll-like receptor2 single-nucleotide polymorphism
carrier; TLR4 SNP, toll-like receptor4 single-nucleotide polymorphism
carrier. Number of patients in each group: non-carrier = 274, TLR4
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Figure 2 TLR4/TLR2 polymorphisms and time course of
perioperative serum concentrations of IL-8 (a), IL-10 (b) and
GM-CSF (c). Sampling times: A: preoperative, B: postoperative at day
of surgery, C: postoperative Day 1. GM-CSF, granulocyte
macrophage-colony stimulating factor; IL, interleukin; TLR2 SNP, toll-
like receptor 2 single-nucleotide polymorphism carrier; TLR4 SNP,
toll-like receptor 4 single-nucleotide polymorphism carrier. Number
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*P < 0.05 compared to A; †P < 0.05 compared to B; ‡P < 0.05
compared to non-carrier.
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pared to non-carriers. Both, TLR4 SNP carriers and
non-carriers showed a significant rise of cortisol serum
levels following cardiac surgery. This rise was preceded/
accompanied by a significant ACTH rise only in non-
carriers. Furthermore, our results link for the first time
a SNP (here: TLR4) with differences in perioperative
t i m ec o u r s e so fI L - 8 ,I L - 1 0a n dG M - C S Fs e r u ml e v e l s ,
that is, in contrast to non-carriers, TLR4 SNP carriers
demonstrated significantly lower immediate postopera-
tive serum concentrations.
Major surgery, for example, cardiac surgery with CPB,
leads to a systemic inflammation which is accompanied
by an activation of the HPA axis [28,29]. A significant
rise of postoperative serum cortisol in cardiac surgery
patients has been described in several studies over the
last decades [30-34]. The rise of endocrine stress mar-
kers seems not to depend on the individual, anticipatory
stress of the patient awaiting surgery, the type of post-
operative respiratory weaning, perioperative beta block-
ade or sufentanil or fentanyl doses [35-39].
Dissociation between cortisol and ACTH levels follow-
ing major surgery has been observed, particularly on the
first postoperative day, whereas ACTH levels spread
strongly immediately after surgery [23,37,40,41]. ACTH
is produced primarily by the anterior pituitary gland.
Alternative sources described in the literature are immu-
nocompetent cells, adrenal gland and inflammatory
sites [42-45]. Furthermore, there are hints, that the
splanchnic nerve is involved in adrenal cortex regulation
[46,47]. As we observed a similar release of cortisol in
TLR4 SNP carriers and non-carriers, the above men-
tioned alternative adrenal cortex stimuli can be dis-
cussed as compensatory mechanisms for cortisol release
in TLR4 SNP carriers. Therefore, one could speculate
that in TLR4 SNP carriers, cortisol release might be
rather locally triggered, while adrenal glands of non-
carriers are mainly controlled by systemic ACTH. In an
ACTH stimulation study in 45 cardiac surgery patients,
11 (25%) had an impaired cortisol response [48]. These
effects could be explained by our findings in that TLR4
SNP carriers were part of the patient population.
Pro-inflammatory cytokines are involved in the release
of corticotropin releasing hormone (CRH) and subse-
quent ACTH release [49]. In CRH-knockout mice viral
infection leads to an ACTH independent corticosterone
response, which is associated with significantly higher
IL-6 plasma concentrations compared to WT mice [50].
This could be interpreted as exaggerated IL-6 levels
compensating for the lack of ACTH. However, in our
study changes in IL-6 levels did not differ between the
groups. Also, GM-CSF is able to trigger cortisol release
[51]; however, we found changes in GM-CSF concentra-
tion to be significantly lower in the TLR4 SNP carrier
group. None of the measured cytokines were found to
be higher up-regulated in the TLR4 SNP group com-
pared to the non-carrier cohort. Therefore, our data
do not support the concept of cytokines being
Table 2 TLR4/TLR2 polymorphisms and time course of perioperative cytomine serum concentrations
Sample times
AB C
IL-1b (pg/ml) non-carrier 8.2 (3.5 to 12.8) 14.4 (9.3 to 19.4) 9.9 (4.8 to 15.0)
TLR4 SNP 6.7 (-4.1 to 17.5) 12.3 (1.2 to 23.5) 11.5 (0.3 to 22.7)
TLR2 SNP 1.2 (-20.2 to 22.6) 29.3 (6.0 to 52.6) 12.4 (-12.0 to 36.9)
IL-2 (pg/ml) non-carrier 2.6 (1.3 to 3.9) 3.0 (1.7 to 4.4) 2.4 (1.0 to 3.8)
TLR4 SNP 2.0 (-1.0 to 5.0) 2.8 (-0.2 to 5.9) 3.3 (0.2 to 6.4)
TLR2 SNP 1.1 (-4.8 to 7.0) 1.8 (-4.6 to 8.2) 1.0 (-5.7 to 7.8)
IL-4 (pg/ml) non-carrier 4.9 (2.7 to 7.1) 4.6 (2.2 to 7.0) 4.2 (1.8 to 6.6)
TLR4 SNP 1.7 (-3.5 to 6.8) 2.0 (-3.3 to 7.3) 1.8 (-3.6 to 7.2)
TLR2 SNP 4.5 (-5.7 to 14.7) 2.4 (-8.7 to 13.5) 3.1 (-8.6 to 14.7)
IL-5 (pg/ml) non-carrier 1.5 (0.7 to 2.4) 2.6 (1.7 to 3.6) 1.5 (0.6 to 2.5)
TLR4 SNP 0.9 (-1.1 to 2.9) 1.4 (-0.7 to 3.5) 0.7 (-1.4 to 2.9)
TLR2 SNP 1.1 (-3.0 to 5.1) 1.4 (-3.0 to 5.8) 0.8 (-3.8 to 5.36)
IL-6 (pg/ml) non-carrier 18.8 (-48.4 to 86.0) 554.1 (481.7 to 626.4)
a 350.4 (277.1 to 423.7)
ab
TLR4 SNP 24.0 (-131.6 to 179.7) 422.5 (262.1 to 583.0)
a 344.7 (182.6 to 506.9)
a
TLR2 SNP 14.3 (-294.0 to 322.7) 696.3 (361.1 to 1031.5)
a 405.7 (54.1 to 757.2)
TNF-a (pg/ml) non-carrier 4.9 (-7.6 to 17.4) 12.9 (-0.6 to 26.3) 8.7 (-4.9 to 22.3)
TLR4 SNP 0.3 (-28.5 to 29.2) 1.9 (-27.8 to 31.7) 1.0 (-29.1 to 31.1)
TLR2 SNP 0.3 (-56.9 to 57.5) 3.4 (-58.8 to 65.5) 1.5 (-63.7 to 66.7)
Sampling times: A: preoperative, B: postoperative at day of surgery, C: postoperative Day 1. IL, interleukin; TLR2 SNP, toll-like receptor2 single-nucleotide
polymorphism carrier; TLR4 SNP, toll-like receptor4 single-nucleotide polymorphism carrier; TNF, tumor necrosis factor.
aP < 0.05 compared to A;
bP < 0.05
compared to B. Data are given as mean and 95% confidence intervals.
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levels to allow sufficient cortisol levels.
Also, in critically ill patients dissociations between
ACTH and cortisol have been described, particularly
from days 4 to 5 post trauma or beginning of sepsis
[52]. A clinical study (Corticus) including patients with
severe sepsis or septic shock demonstrated that survi-
vors had lower baseline cortisol levels and significant
higher Δmax (that is, peak cortisol following ACTH sti-
mulation minus baseline cortisol) compared to nonsur-
vivors [53]. In critically ill, for example, septic patients,
adrenal insufficiency can occur and it has been postu-
lated that particularly these patients could benefit from
a therapy with glucosteroids [54,55]. However, the diag-
nosis of adrenal insufficiency in critically ill is difficult
and there is still an ongoing search for an adequate
diagnostic tool. The diagnosis of adrenal insufficiency in
septic patients examined in multicenter trials is compli-
cated by a high inter-assay variation [56]. In a recently
published recommendation upon the diagnosis and
management of corticosteroid insufficiency in critically
ill adult patients, the standard ACTH stimulation test
for diagnosing adrenal insufficiency is not recommended
to be performed as a routine [57]. In literature, the pre-
valence of adrenal insufficiency in critically ill patients
varies widely between the studies (0 to 77%) [52,57,58].
The question arising from our results is: How do adre-
nal glands from TLR4 SNP carriers respond to an
ACTH stimulation test as they are obviously releasing
cortisol less dependent/independent from ACTH during
systemic inflammation? Does ACTH stimulation result
in even higher cortisol serum levels or are adrenal
glands of TLR4 SNP carriers insensitive to ACTH? This
should be taken into consideration when interpreting
completed, and planning for new clinical trials on HPA
axis regulation in septic patients. Particularly, consider-
ing the fact that TLR4 SNP carriers demonstrate a
higher risk for developing sepsis, that is, the frequency
of TLR4 SNP carriers in a septic patient cohort is higher
(approximately 20%) compared to the normal popula-
tion or, for example, cardiac surgical patients [59-61].
A perioperative rise of several cytokines following
major/cardiac surgery is well described [19,28,29,62].
Regarding perioperative TNF-a and IL-6 plasma concen-
trations and the influence of TLR4 SNP (Asp299Gly/
Thr399Ile), our findings are similar to previous trials. In
abdominal surgical patients neither non-carriers nor
TLR4 SNP carriers showed a significant rise in TNF-a
postoperatively. However, both cohorts demonstrated a
significant IL-6 rise compared to preoperative baseline
concentrations. Neither TNF-a, nor IL-6 plasma concen-
trations differed significantly between non-carriers and
TLR4 SNP carriers [63]. Furthermore, there was no dif-
ference of IL-6 levels in a healthy population (8 TLR4
SNP vs 49 non-carriers) treated with low dose LPS [64].
A diminished Human Leukocyte Antigen (HLA-DR)
expression on monocytes and B-lymphocytes following
cardiac surgery can in vitro be reversed by GM-CSF [65].
One could therefore speculate, that TLR4 SNP carriers
would express less HLA-DR, possibly making them more
susceptible to postoperative infections. On the other
hand IL-10 can reverse HLA-DR up-regulation [66].
Translated to our results this would mean better immune
competence of TLR4 SNP carriers. Post surgery and/or
trauma IL-8 and IL-10 plasma levels are significantly
higher in nonsurvivors compared to survivors [67], which
would translated to our study result in a higher mortality
in the non-carrier group. However, our study did not
find differences in 28-day outcome between the cohorts,
which might be due to an underpowered sample size.
Ex vivo stimulation of whole blood or isolated mono-
cytes revealed similar cytokine responses as observed in
our study: The presence of TLR4 SNP did not influence
the LPS induced release of TNF-a,I L - 1 b or IL-6 com-
pared to non-carriers. However, comparable to our
results, TLR4 SNP led to a reduced IL-10 release
[68,69]. With IL-10 enhancing ACTH release [70], the
significant lower rise of IL-10 in TLR4 SNP carriers
could have accounted for the absence of a significant
change in ACTH levels in this genotype.
During cardiac surgery, phases of hypoperfusion with
consecutive tissue hypoxia occur. Hypoxia induces
expression and increases signaling of TLRs [71]. This
seems to be particularly true for TLR2 and TLR6 [72].
You could therefore speculate that hypoxia induced
TLR2 expression is negatively influenced by the pre-
sence of TLR2 SNP. The TLR2 SNP carrier group in
this study is probably too small to estimate whether the
SNP for TLR2 would have an effect on, for example,
cytokine release. Serum concentrations of cytokines
investigated in this study do not differ between non-car-
riers and TLR2 SNP carriers.
A study in patients (n =9 4 )b e i n ga d m i t t e dt ot h e
intensive care unit for various reasons (sepsis, cardiovas-
cular failure, pancreatitis, respiratory failures, and so on)
failed to demonstrate a correlation between SNP TLR4
Asp299Gly and length of stay (hospital or intensive
care). However, mortality was higher in TLR4 SNP car-
riers [61]. Our study did not find a correlation between
hospital or intensive care length of stay (data not
shown) or mortality (see results) and TLR2 or TLR4
SNP. As a further limitation of this study, the TLR2
SNP carrier group compared to the non-carrier group is
too small to draw major conclusions. Also, the study is
underpowered for detecting significant differences in
morbidity or mortality between the cohorts. Further stu-
dies are needed to determine if the observations made
in this study have any impact on clinical outcome.
Koch et al. Critical Care 2011, 15:R109
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Page 7 of 10W i t ht h i ss t u d yw et r a n s l a t e do b s e r v a t i o n sm a d ei n
animals to a clinical scenario. In TLR2 and TLR4 knock-
out mice we demonstrated the altered regulation of
HPA axis and cytokines during systemic inflammation.
In patients, polymorphisms of TLR2 and TLR4 influence
HPA axis and cytokine response to surgical stress, that
is, systemic inflammation.
Conclusions
In conclusion, this clinical study in cardiac surgical
patients demonstrates a diminished perioperative ACTH
release in TLR4 SNP carrying patients. Carriers and
non-carriers, however, demonstrated the same transient,
perioperative rise in cortisol serum concentrations, indi-
cating that in TLR4 polymorphism carriers, cortisol
release seems to be less dependent or even independent
of systemic ACTH concentrations. These findings
should be considered when diagnosing and treating
adrenal insufficiency in patients with systemic inflamma-
tion, for example, sepsis. Furthermore, TLR4 SNP car-
riers demonstrated a significantly reduced release of the
cytokines IL-8, IL-10 and GM-CSF compared to non-
carriers. TNF-a,I L - 1 b, IL-2, IL-4, IL-5 and IL-6 did not
differ between TLR4 SNP carriers and non-carriers.
Key messages
￿ Cardiac surgical patients carrying a genetic varia-
tion of TLR4 demonstrate diminished perioperative
ACTH release.
￿ However, postoperative cortisol rise did not differ
from non-carriers, indicating ACTH not to be the
primary stimulus for perioperative cortisol release in
TLR4 carriers.
￿ This finding might have impact on interpreting
previous and planning new studies investigating
adrenal insufficiency in patients with systemic
inflammation (for example, sepsis).
￿ TLR4 polymorphism carriers demonstrated lower
postoperative peaks of the cytokines IL-8, IL-10 and
GM-CSF.
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